Profile - To The Moon

Adwinwee88

Posts · 3Posts · 3
Following · 0Following · 0
Followers · 0Followers · 0

- Adwinwee88Adwinwee88
  ·2021-07-22
  [Miser] [Miser] [Miser] [Duh]
  Uber and Lyft drivers strike for a day, say earnings are declining despite driver shortage
  'Long-term drivers have seen substantial declines in pay' despite rising fares and demand, organizer
  Uber and Lyft drivers strike for a day, say earnings are declining despite driver shortage
  33 Comment
  Like
  Share
  Report
- Adwinwee88Adwinwee88
  ·2021-07-22
  $iQiyi Inc.(IQ)$hopefully good will up
  35 Comment
  Like
  Share
  Report
- Adwinwee88Adwinwee88
  ·2021-07-22
  Nice
  4 Biotech Stocks That Could Be Bargains
  Biotech stocks have had an uneven 2021 so far. One major biotech fund, the iShares Nasdaq Biotechnol
  4 Biotech Stocks That Could Be Bargains
  64 Comment
  2
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3586411303282160","uuid":"3586411303282160","gmtCreate":1623384575610,"gmtModify":1625110141483,"name":"Adwinwee88","pinyin":"adwinwee88","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/b7e25c9cf3841724ca8eb5e50841acea","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":5,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":172107787,"gmtCreate":1626942082449,"gmtModify":1703480992818,"author":{"id":"3586411303282160","authorId":"3586411303282160","name":"Adwinwee88","avatar":"https://static.tigerbbs.com/b7e25c9cf3841724ca8eb5e50841acea","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586411303282160","authorIdStr":"3586411303282160"},"themes":[],"htmlText":"[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;[Duh]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;[Duh]&nbsp;","text":"[Miser] [Miser] [Miser] [Duh]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172107787","repostId":"2153614623","repostType":4,"repost":{"id":"2153614623","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1626936180,"share":"https://ttm.financial/m/news/2153614623?lang=&edition=fundamental","pubTime":"2021-07-22 14:43","market":"hk","language":"en","title":"Uber and Lyft drivers strike for a day, say earnings are declining despite driver shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=2153614623","media":"Dow Jones","summary":"'Long-term drivers have seen substantial declines in pay' despite rising fares and demand, organizer","content":"<blockquote>\n 'Long-term drivers have seen substantial declines in pay' despite rising fares and demand, organizer says as protests planned for 10 cities seek passage of PRO Act in congress.\n</blockquote>\n<p>SAN FRANCISCO -- Ride-hailing drivers across the country went on strike Wednesday, saying their earnings are declining and calling on the U.S. Senate to pass the PRO Act to allow them to organize.</p>\n<p>In California, drivers said the promises Uber Technologies Inc. <a href=\"https://laohu8.com/S/UBER\">$(UBER)$</a> and Lyft Inc. <a href=\"https://laohu8.com/S/LYFT\">$(LYFT)$</a> made last year during the companies' record-breaking Proposition 22 campaign , which offered guaranteed earnings and health-care stipends, allowing the companies to circumvent a state law that would've required them to treat drivers as employees instead of independent contractors.</p>\n<p>For more: Gig workers to see pay changes, customers to see higher prices after Prop. 22 passes</p>\n<p>Drivers in the state say they still lack decent pay and benefits, and are asking federal lawmakers to act so they can gain the right to join unions and collectively bargain. As Uber and Lyft acknowledge that prices for rides are high and that they don't have enough drivers to meet rising demand amid the COVID-19 pandemic, some drivers still contend they are seeing declining rates for their efforts.</p>\n<p>Drivers stopped working and converged at Uber headquarters in San Francisco on Wednesday afternoon, chanting \"Prop. 22, somebody lied to you.\"</p>\n<p>Ibrahim Diallo, an immigrant from Mali who lives in San Francisco, told MarketWatch at the rally that he has driven for Uber since 2015, and his earnings have decreased over the years. Diallo said he's having to work more hours than before to survive, and with the recent shortage of drivers, he said it has been hard to take breaks.</p>\n<p>\"Am I a robot?\" he asked. \"If you don't take a break, you'll get tired and could get in an accident.\"</p>\n<p>Esterphanie St. Juste, a longtime driver and organizer with Rideshare Drivers United (RDU) in Los Angeles, said Uber has reduced what it pays drivers out of Los Angeles International Airport to 32 cents a mile.</p>\n<p>\"Can you imagine being paid 32 cents for anything in the U.S., and with gas prices rising?\" she asked.</p>\n<p>Brian Dolber, an associate professor at California State University, San Marcos, and an organizer with RDU, said drivers out of LAX were previously making 58 cents a mile.</p>\n<p>\"Prior to that it was 80 cents per mile, and years before that it was $1.50,\" Dolber said. \"Long-term drivers have seen substantial declines in pay. These companies hooked people in, where people were making a decent living, but without any legal protections, drivers saw their rates lowered repeatedly.\"</p>\n<p>Drivers also demonstrated at the L.A. airport on Wednesday, and similar efforts were planned in eight other cities, according to RDU: San Diego, Austin, Boston, Cleveland, Las Vegas, Pittsburgh, Denver and Baltimore.</p>\n<p>Uber and Lyft pushed back against the drivers' allegations Wednesday.</p>\n<p>\"Drivers are busier now than they were even before the pandemic started,\" a Lyft spokesman said. \"In our top markets, drivers are making more than $30 an hour, substantially higher than pre-COVID.\" An Uber spokeswoman said the median earnings for Uber drivers when they are on the app is $32.33 an hour.</p>\n<p>The drivers' action comes ahead of a Senate committee hearing on HR 482 , has so far fallen short of the support it needs to be taken up by the Senate.</p>\n<p>\"The only job of a business is to make profit for their owners and stockholders,\" St. Juste told MarketWatch on Wednesday. \"The PRO Act will give us our voice and give us the power to make changes.\"</p>\n<p>Both gig companies touted \"driver independence\" in their response to drivers urging lawmakers to pass the PRO Act.</p>\n<p>\"Lyft is fighting to expand benefits and protections for drivers in a way that allows them to keep their independence,\" that company's spokesman said. Uber's spokeswoman said: \"Uber believes we should advance policies that improve independent work, instead of eliminating it.\"</p>\n<p>The San Francisco rally included politicians and activists. California Assemblyman Ash Kalra, a Democrat, called the PRO Act \"a backstop\" against \"the downward spiral of our society.\"</p>\n<p>\"[The gig companies] can just spend a bunch of money and make their own laws,\" he said.</p>\n<p>Eddy Hernandez, a former Uber engineer who quit his job in solidarity with drivers during last year's Proposition 22 campaign, said that \"tech workers need to demand an end to second-class employment status.\"</p>\n<p>\"How does Uber know what drivers want if they don't have a voice on the job?\" he asked.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uber and Lyft drivers strike for a day, say earnings are declining despite driver shortage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUber and Lyft drivers strike for a day, say earnings are declining despite driver shortage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-07-22 14:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n 'Long-term drivers have seen substantial declines in pay' despite rising fares and demand, organizer says as protests planned for 10 cities seek passage of PRO Act in congress.\n</blockquote>\n<p>SAN FRANCISCO -- Ride-hailing drivers across the country went on strike Wednesday, saying their earnings are declining and calling on the U.S. Senate to pass the PRO Act to allow them to organize.</p>\n<p>In California, drivers said the promises Uber Technologies Inc. <a href=\"https://laohu8.com/S/UBER\">$(UBER)$</a> and Lyft Inc. <a href=\"https://laohu8.com/S/LYFT\">$(LYFT)$</a> made last year during the companies' record-breaking Proposition 22 campaign , which offered guaranteed earnings and health-care stipends, allowing the companies to circumvent a state law that would've required them to treat drivers as employees instead of independent contractors.</p>\n<p>For more: Gig workers to see pay changes, customers to see higher prices after Prop. 22 passes</p>\n<p>Drivers in the state say they still lack decent pay and benefits, and are asking federal lawmakers to act so they can gain the right to join unions and collectively bargain. As Uber and Lyft acknowledge that prices for rides are high and that they don't have enough drivers to meet rising demand amid the COVID-19 pandemic, some drivers still contend they are seeing declining rates for their efforts.</p>\n<p>Drivers stopped working and converged at Uber headquarters in San Francisco on Wednesday afternoon, chanting \"Prop. 22, somebody lied to you.\"</p>\n<p>Ibrahim Diallo, an immigrant from Mali who lives in San Francisco, told MarketWatch at the rally that he has driven for Uber since 2015, and his earnings have decreased over the years. Diallo said he's having to work more hours than before to survive, and with the recent shortage of drivers, he said it has been hard to take breaks.</p>\n<p>\"Am I a robot?\" he asked. \"If you don't take a break, you'll get tired and could get in an accident.\"</p>\n<p>Esterphanie St. Juste, a longtime driver and organizer with Rideshare Drivers United (RDU) in Los Angeles, said Uber has reduced what it pays drivers out of Los Angeles International Airport to 32 cents a mile.</p>\n<p>\"Can you imagine being paid 32 cents for anything in the U.S., and with gas prices rising?\" she asked.</p>\n<p>Brian Dolber, an associate professor at California State University, San Marcos, and an organizer with RDU, said drivers out of LAX were previously making 58 cents a mile.</p>\n<p>\"Prior to that it was 80 cents per mile, and years before that it was $1.50,\" Dolber said. \"Long-term drivers have seen substantial declines in pay. These companies hooked people in, where people were making a decent living, but without any legal protections, drivers saw their rates lowered repeatedly.\"</p>\n<p>Drivers also demonstrated at the L.A. airport on Wednesday, and similar efforts were planned in eight other cities, according to RDU: San Diego, Austin, Boston, Cleveland, Las Vegas, Pittsburgh, Denver and Baltimore.</p>\n<p>Uber and Lyft pushed back against the drivers' allegations Wednesday.</p>\n<p>\"Drivers are busier now than they were even before the pandemic started,\" a Lyft spokesman said. \"In our top markets, drivers are making more than $30 an hour, substantially higher than pre-COVID.\" An Uber spokeswoman said the median earnings for Uber drivers when they are on the app is $32.33 an hour.</p>\n<p>The drivers' action comes ahead of a Senate committee hearing on HR 482 , has so far fallen short of the support it needs to be taken up by the Senate.</p>\n<p>\"The only job of a business is to make profit for their owners and stockholders,\" St. Juste told MarketWatch on Wednesday. \"The PRO Act will give us our voice and give us the power to make changes.\"</p>\n<p>Both gig companies touted \"driver independence\" in their response to drivers urging lawmakers to pass the PRO Act.</p>\n<p>\"Lyft is fighting to expand benefits and protections for drivers in a way that allows them to keep their independence,\" that company's spokesman said. Uber's spokeswoman said: \"Uber believes we should advance policies that improve independent work, instead of eliminating it.\"</p>\n<p>The San Francisco rally included politicians and activists. California Assemblyman Ash Kalra, a Democrat, called the PRO Act \"a backstop\" against \"the downward spiral of our society.\"</p>\n<p>\"[The gig companies] can just spend a bunch of money and make their own laws,\" he said.</p>\n<p>Eddy Hernandez, a former Uber engineer who quit his job in solidarity with drivers during last year's Proposition 22 campaign, said that \"tech workers need to demand an end to second-class employment status.\"</p>\n<p>\"How does Uber know what drivers want if they don't have a voice on the job?\" he asked.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBER":"优步","LYFT":"Lyft, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153614623","content_text":"'Long-term drivers have seen substantial declines in pay' despite rising fares and demand, organizer says as protests planned for 10 cities seek passage of PRO Act in congress.\n\nSAN FRANCISCO -- Ride-hailing drivers across the country went on strike Wednesday, saying their earnings are declining and calling on the U.S. Senate to pass the PRO Act to allow them to organize.\nIn California, drivers said the promises Uber Technologies Inc. $(UBER)$ and Lyft Inc. $(LYFT)$ made last year during the companies' record-breaking Proposition 22 campaign , which offered guaranteed earnings and health-care stipends, allowing the companies to circumvent a state law that would've required them to treat drivers as employees instead of independent contractors.\nFor more: Gig workers to see pay changes, customers to see higher prices after Prop. 22 passes\nDrivers in the state say they still lack decent pay and benefits, and are asking federal lawmakers to act so they can gain the right to join unions and collectively bargain. As Uber and Lyft acknowledge that prices for rides are high and that they don't have enough drivers to meet rising demand amid the COVID-19 pandemic, some drivers still contend they are seeing declining rates for their efforts.\nDrivers stopped working and converged at Uber headquarters in San Francisco on Wednesday afternoon, chanting \"Prop. 22, somebody lied to you.\"\nIbrahim Diallo, an immigrant from Mali who lives in San Francisco, told MarketWatch at the rally that he has driven for Uber since 2015, and his earnings have decreased over the years. Diallo said he's having to work more hours than before to survive, and with the recent shortage of drivers, he said it has been hard to take breaks.\n\"Am I a robot?\" he asked. \"If you don't take a break, you'll get tired and could get in an accident.\"\nEsterphanie St. Juste, a longtime driver and organizer with Rideshare Drivers United (RDU) in Los Angeles, said Uber has reduced what it pays drivers out of Los Angeles International Airport to 32 cents a mile.\n\"Can you imagine being paid 32 cents for anything in the U.S., and with gas prices rising?\" she asked.\nBrian Dolber, an associate professor at California State University, San Marcos, and an organizer with RDU, said drivers out of LAX were previously making 58 cents a mile.\n\"Prior to that it was 80 cents per mile, and years before that it was $1.50,\" Dolber said. \"Long-term drivers have seen substantial declines in pay. These companies hooked people in, where people were making a decent living, but without any legal protections, drivers saw their rates lowered repeatedly.\"\nDrivers also demonstrated at the L.A. airport on Wednesday, and similar efforts were planned in eight other cities, according to RDU: San Diego, Austin, Boston, Cleveland, Las Vegas, Pittsburgh, Denver and Baltimore.\nUber and Lyft pushed back against the drivers' allegations Wednesday.\n\"Drivers are busier now than they were even before the pandemic started,\" a Lyft spokesman said. \"In our top markets, drivers are making more than $30 an hour, substantially higher than pre-COVID.\" An Uber spokeswoman said the median earnings for Uber drivers when they are on the app is $32.33 an hour.\nThe drivers' action comes ahead of a Senate committee hearing on HR 482 , has so far fallen short of the support it needs to be taken up by the Senate.\n\"The only job of a business is to make profit for their owners and stockholders,\" St. Juste told MarketWatch on Wednesday. \"The PRO Act will give us our voice and give us the power to make changes.\"\nBoth gig companies touted \"driver independence\" in their response to drivers urging lawmakers to pass the PRO Act.\n\"Lyft is fighting to expand benefits and protections for drivers in a way that allows them to keep their independence,\" that company's spokesman said. Uber's spokeswoman said: \"Uber believes we should advance policies that improve independent work, instead of eliminating it.\"\nThe San Francisco rally included politicians and activists. California Assemblyman Ash Kalra, a Democrat, called the PRO Act \"a backstop\" against \"the downward spiral of our society.\"\n\"[The gig companies] can just spend a bunch of money and make their own laws,\" he said.\nEddy Hernandez, a former Uber engineer who quit his job in solidarity with drivers during last year's Proposition 22 campaign, said that \"tech workers need to demand an end to second-class employment status.\"\n\"How does Uber know what drivers want if they don't have a voice on the job?\" he asked.","news_type":1},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172107812,"gmtCreate":1626942048936,"gmtModify":1703480991848,"author":{"id":"3586411303282160","authorId":"3586411303282160","name":"Adwinwee88","avatar":"https://static.tigerbbs.com/b7e25c9cf3841724ca8eb5e50841acea","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586411303282160","authorIdStr":"3586411303282160"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IQ\">$iQiyi Inc.(IQ)$</a>hopefully good will up&nbsp;","listText":"<a href=\"https://laohu8.com/S/IQ\">$iQiyi Inc.(IQ)$</a>hopefully good will up&nbsp;","text":"$iQiyi Inc.(IQ)$hopefully good will up","images":[{"img":"https://static.tigerbbs.com/b7e82332b3f4ceef9a0e0a3d2e93323a","width":"1284","height":"2457"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172107812","isVote":1,"tweetType":1,"viewCount":35,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":172104872,"gmtCreate":1626941935296,"gmtModify":1703480990713,"author":{"id":"3586411303282160","authorId":"3586411303282160","name":"Adwinwee88","avatar":"https://static.tigerbbs.com/b7e25c9cf3841724ca8eb5e50841acea","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586411303282160","authorIdStr":"3586411303282160"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172104872","repostId":"1197792637","repostType":4,"repost":{"id":"1197792637","pubTimestamp":1626941717,"share":"https://ttm.financial/m/news/1197792637?lang=&edition=fundamental","pubTime":"2021-07-22 16:15","market":"us","language":"en","title":"4 Biotech Stocks That Could Be Bargains","url":"https://stock-news.laohu8.com/highlight/detail?id=1197792637","media":"Barron's","summary":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnol","content":"<p>Biotech stocks have had an uneven 2021 so far.</p>\n<p>One major biotech fund, the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b>, which focuses on the bigger biotech players, is up 9%, just behind the&nbsp;S&amp;P 500 index,which is up 14.3%. Another important fund, the<b>&nbsp;<a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b>, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.</p>\n<p>The success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.</p>\n<p>Picking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.</p>\n<p>For those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.</p>\n<h3><b>4 Undervalued Biotech Stocks</b></h3>\n<p>These are the four biotech stocks in the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b> and the <b><a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b> with market values over $5 billion that trade the farthest below their average analyst price targets.</p>\n<table>\n <thead>\n  <tr>\n   <th>Company / Ticker</th>\n   <th>Recent Price</th>\n   <th>Average Target Price</th>\n   <th>Implied Gain</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>TG Therapeutics / TGTX</td>\n   <td>$37.32</td>\n   <td>$75.88</td>\n   <td>103.3%</td>\n  </tr>\n  <tr>\n   <td>Vir Biotechnology / VIR</td>\n   <td>$37.91</td>\n   <td>$74.29</td>\n   <td>96.0%</td>\n  </tr>\n  <tr>\n   <td>Ultragenyx Pharmaceutical / RARE</td>\n   <td>$85.49</td>\n   <td>$153.12</td>\n   <td>79.1%</td>\n  </tr>\n  <tr>\n   <td>Exelixis / EXEL</td>\n   <td>$16.67</td>\n   <td>$29.54</td>\n   <td>77.2%</td>\n  </tr>\n </tbody>\n</table>\n<p><i>Source: FactSet</i></p>\n<p>Analysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we&nbsp;looked at the five health-care stocks in the S&amp;P 500 that trade the farthest below their average analyst&nbsp;price&nbsp;targets.</p>\n<p>This time, we’ve looked at the stocks in the SPDR S&amp;P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.</p>\n<p>We set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.</p>\n<p>The stocks that passed the screen are&nbsp;<b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology, Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical</a></b>, and<b>&nbsp;<a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.</p>\n<p>The stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.</p>\n<p><b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b> stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.</p>\n<p>Analysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.</p>\n<p>The average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.</p>\n<p>Another stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy&nbsp;jointly developed by Vir and&nbsp;<b><a href=\"https://laohu8.com/S/GSK\">GlaxoSmithKline PLC</a></b> to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.</p>\n<p>Vir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.</p>\n<p>Of the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.</p>\n<p>Also on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.</p>\n<p>The company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.</p>\n<p>“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.</p>\n<p>The average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.</p>\n<p>The final stock to pass our screen was <b><a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.</p>\n<p>The average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Biotech Stocks That Could Be Bargains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Biotech Stocks That Could Be Bargains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 16:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which ...</p>\n\n<a href=\"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯","TGTX":"TG Therapeutics Inc.","XBI":"SPDR S&P Biotech ETF","VIR":"Vir Biotechnology, Inc.","RARE":"Ultragenyx Pharmaceutical Inc","IBB":"生物科技指数ETF-iShares Nasdaq","GSK":"葛兰素史克"},"source_url":"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197792637","content_text":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which is up 14.3%. Another important fund, the Spdr S&P Biotech Etf, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.\nThe success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.\nPicking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.\nFor those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.\n4 Undervalued Biotech Stocks\nThese are the four biotech stocks in the iShares Nasdaq Biotechnology ETF and the Spdr S&P Biotech Etf with market values over $5 billion that trade the farthest below their average analyst price targets.\n\n\n\nCompany / Ticker\nRecent Price\nAverage Target Price\nImplied Gain\n\n\n\n\nTG Therapeutics / TGTX\n$37.32\n$75.88\n103.3%\n\n\nVir Biotechnology / VIR\n$37.91\n$74.29\n96.0%\n\n\nUltragenyx Pharmaceutical / RARE\n$85.49\n$153.12\n79.1%\n\n\nExelixis / EXEL\n$16.67\n$29.54\n77.2%\n\n\n\nSource: FactSet\nAnalysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we looked at the five health-care stocks in the S&P 500 that trade the farthest below their average analyst price targets.\nThis time, we’ve looked at the stocks in the SPDR S&P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.\nWe set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.\nThe stocks that passed the screen are TG Therapeutics, Vir Biotechnology, Inc., Ultragenyx Pharmaceutical, and Exelixis, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.\nThe stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.\nTG Therapeutics stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.\nAnalysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.\nThe average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.\nAnother stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy jointly developed by Vir and GlaxoSmithKline PLC to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.\nVir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.\nOf the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.\nAlso on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.\nThe company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.\n“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.\nThe average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.\nThe final stock to pass our screen was Exelixis, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.\nThe average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.","news_type":1},"isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}